Titre:
  • Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
Auteur:Eschenhagen, Thomas; Force, Thomas; Ewer, Michael S; de Keulenaer, Gilles W; Suter, Thomas; Anker, Stefan D; Avkiran, Metin; Azambuja, Evandro; Balligand, Jean-Luc; Brutsaert, Dirk L; Condorelli, Gianluigi; Hansen, Arne; Heymans, Stephane; Hill, Joseph A; Hirsch, Emilio; Hilfiker-Kleiner, Denise; Janssens, Stef; de Jong, Steven; Neubauer, Gitte; Pieske, Burkert; Ponikowski, Piotr; Pirmohamed, Munir; Rauchhaus, Mathias; Sawyer, Douglas; Sugden, Peter H; Wojta, Johann; Zannad, Faiez; Shah, Ajay M
Informations sur la publication:European journal of heart failure, 13, 1, page (1-10)
Statut de publication:Publié, 2011-01
Sujet CREF:Cancérologie
Mots-clés:Anthracyclines
Cardio-oncology
Cardiotoxicity
Consensus statement
Heart failure
Targeted therapy
MeSH keywords:Anthracyclines -- adverse effects -- therapeutic use
Antibodies, Monoclonal -- adverse effects -- therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents -- adverse effects -- therapeutic use
Cardiology -- standards
Cardiotoxins
Cardiovascular System -- drug effects
Education
Europe
Heart Failure -- chemically induced
Humans
Neoplasms -- drug therapy
Practice Guidelines as Topic
Receptor, Epidermal Growth Factor -- drug effects
Risk Factors
Sirolimus -- antagonists & inhibitors
Note générale:Journal Article
Research Support, Non-U.S. Gov't
Review
FLWIN
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1388-9842
info:doi/10.1093/eurjhf/hfq213
info:pii/hfq213
info:scp/78650383580
info:pmid/21169385